Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. The Company is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active research pipeline of other human enzyme-based approaches in both therapeutic areas.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Pegzilarginase for Arginase I Deficiency
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):